Lipocine is trading at $2.21, up 5.74%; no clear company-specific catalyst surfaced in the available news search for September 29, 2026. - The reported Phase 3 study announcement dates to September 14 and does not establish a direct reason for this session’s move. - Broader indexes are mixed, with no same-direction market move above 0.5% to explain the gain. - Trading volume or activity level was not available in the provided information.